Major clinical news will be May 13 when abstracts are released on ASCO.org. The ASCO Annual Meeting is the largest in the cancer field, and brings together 30,000 oncology professionals from around the world. We will find out if the GEN-1 abstract are included in the Oral Abstract Session (Gynecologic Cancer) for June 1, which would mean it represents important clinical research. The odds of that happening are pretty good from the info Celsion has released so for on the clinical research they have done on Gen-1. I wouldn't doubt a dollar price swing up if news it will be presented at ASCO. Also, even though it's public info Celsion will start selling ThermoDox to China sometime in May or June-look for a nice little bump when press release comes out soon. This would be a good time to add to your position. With everything they have in their pipeline we just might never see this low of a share price again.
ONE MORE TIME ;;
Celsion is financially stable for the next 2 years.
The obvious binary event is ASCO, but clinical evidence tilts the odds in favor of a positive catalyst.
The market ignored an announcement that says Celsion could be in the business of selling ThermoDox®
3 years before approval. MyTomorrows is an online patient platform that is creating freedom of choice for patients with unmet medical needs by offering earlier access to medicines that show promising results during clinical trials, but are not officially registered yet. With the support of their doctors, patients who suffer from cancer, a neurological disorder, a rare disease or a severe depression, can have earlier access to such medicines.
CLSN--HEAT STUDY 2-23-15 ;;; "The consistent and improving evidence of an overall survival benefit not only reinforces their interest, but also suggests that ThermoDox should be considered conditionally in patients presenting with unresectable, intermediate stage disease."
As of January 15, 2015, the latest quarterly overall survival (OS) analysis demonstrated that in a large, well bounded, subgroup of patients (n=285, 41% of the study patients), the combination of ThermoDox® and optimized RFA provided a 59% improvement in OS compared to optimized RFA alone. The Hazard Ratio at this analysis is 0.628 (95% CI 0.420 – 0.939) with a p-value of 0.02.
Estimated Enrollment: 20
Study Start Date: February 2013
Estimated Study Completion Date: August 2015
Estimated Primary Completion Date: June 2015 (Final data collection date for primary outcome measure)
I tried these guys and after my first week I am up 900% in gains. Ultimate Stock Alerts (search Google for them)
an opportunity to exercise free options isn't insider buying
flipping part of your free shares sends out no buy signals
whenever clsn insiders buy, its typically well under 10k shares each.
when we see ceo fork out 100,000 shares with his own life savings,
or a group of insiders suddenly buy 25,000+ shares each
I will buy long shares and join the pump dudes
i am no longer short clsn,
just watching, waiting
if it jumps and you make a few bucks, good for each of you
You've clearly been more accurate than most in the past. Who knows what will transpire in the future?
Though there is not massive insider buying, there were a number(9) insiders who filed form 4 on 'ole st paddy's day to purchase hundred of thousands(I didn't tally) of options at $2.45/sh, Additionally, the institutional dive in vs bail out ratio for the last reporting quarter(12/31/14) is 587,358sh/180,638sh. Short interest stood at 471,563 sh on 2/27/15 vs 2,274,656 a year ago.
Don't know if it means anything, just saying.
2nd observation tanakvu, if clsn revenues were about to explode, you'd see massive insider buying, which isn't happening. if they start buying in mass, then pump away.
"Period Ending Dec 31, 2014 Dec 31, 2013 Dec 31, 2012
Total Revenue $500,000 $500,000 $0
Do you see a pattern forming?
$6 billion? apparently you are on the wrong message board
Annual income "my Tomorrows" are $ 6 billion
The contract with "myTomorrows" allows commercial plasma therapy on the market with a population of 550 million people and 25,000 cases annually affected. Competitive alternative therapies, such as by Celsion is not.
What can we expect? Perhaps treatments in 1000 patients a year? Or more? At a price ???? $ 20,000 per person? Or more?
We'll see! Forecasts are promising!